Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of ObsEva patents

List of ObsEva patents

List of Nerviano Medical Sciences patents

List of Ixia (company) patents

List of IntelliVision (company) patents

FinTech accelerators and incubators

Companies in the Hair salon industry

Patents where

Current Assignee

Name

is

ObsEva

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11419851 Oral formulations of pyrrolidine derivatives		ObsEva	ObsEva		United States Patent and Trademark Office	11419851	August 23, 2022
	‌ US Patent 11524003 Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof	Patent 11524003 was granted and assigned to ObsEva on December, 2022 by the United States Patent and Trademark Office.	ObsEva	ObsEva		United States Patent and Trademark Office	11524003	December 13, 2022
	‌ US Patent 11312683 Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists	Patent 11312683 was granted and assigned to ObsEva on April, 2022 by the United States Patent and Trademark Office.	ObsEva	ObsEva		United States Patent and Trademark Office	11312683	April 26, 2022
	‌ US Patent 10047048 Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists	Patent 10047048 was granted and assigned to ObsEva on August, 2018 by the United States Patent and Trademark Office.	ObsEva	ObsEva		United States Patent and Trademark Office	10047048	August 14, 2018
	‌ US Patent 10555934 Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof	Patent 10555934 was granted and assigned to ObsEva on February, 2020 by the United States Patent and Trademark Office.	ObsEva	ObsEva		United States Patent and Trademark Office	10555934	February 11, 2020
	‌ US Patent 9962367 Oral formulations of pyrrolidine derivatives	Patent 9962367 was granted and assigned to ObsEva on May, 2018 by the United States Patent and Trademark Office.	ObsEva	ObsEva		United States Patent and Trademark Office	9962367	May 8, 2018
	‌ US Patent 9670155 Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists	Patent 9670155 was granted and assigned to ObsEva on June, 2017 by the United States Patent and Trademark Office.	ObsEva	ObsEva		United States Patent and Trademark Office	9670155	June 6, 2017
	‌ US Patent 10752583 Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same		ObsEva	ObsEva		United States Patent and Trademark Office	10752583	August 25, 2020
	‌ US Patent 10604482 Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists		ObsEva	ObsEva		United States Patent and Trademark Office	10604482	March 31, 2020
	‌ US Patent 10478420 Oral formulations of pyrrolidine derivatives	Patent 10478420 was granted and assigned to ObsEva on November, 2019 by the United States Patent and Trademark Office.	ObsEva	ObsEva		United States Patent and Trademark Office	10478420	November 19, 2019
	‌ US Patent 9718772 Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same	Patent 9718772 was granted and assigned to ObsEva on August, 2017 by the United States Patent and Trademark Office.	ObsEva	ObsEva		United States Patent and Trademark Office	9718772	August 1, 2017

11 results

0 selected

11 results

0 selected